Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 218-712-7 | CAS number: 2217-40-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: OECD guideline study conducted according to GLP.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 006
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
Test material
- Reference substance name:
- 1,2,3,4-tetrahydro-1-naphthylamine
- EC Number:
- 218-712-7
- EC Name:
- 1,2,3,4-tetrahydro-1-naphthylamine
- Cas Number:
- 2217-40-5
- Molecular formula:
- C10H13N
- IUPAC Name:
- 1,2,3,4-tetrahydronaphthalen-1-amine
- Details on test material:
- Name of test substance: 1-Aminotetralin
Test substance No.: 05/0560-1
Batch Identification: 7346-05/67 Hauptlauf
Purity: 98.2 area%
Homogeneity: The test substance was homogeneous by visual inspection.
Storage stability: The stability under storage conditions over the study period was guaranteed by the sponsor, and the sponsor holds this responsibility.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Doses:
- 300, 500 mg/kg
- No. of animals per sex per dose:
- 3
- Control animals:
- no
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 300 - 500 mg/kg bw
- Mortality:
- Two animals of the 500 mg/kg administration group were found dead within 4 hours after application.
No mortality occurred in the 300 mg/kg administration groups. - Clinical signs:
- other: Clinical observation in one animal of the 500 mg/kg administration group revealed poor general state, dyspnoea, lateral position, clonic convulsions and salivation and were observed from hour 1 through to hour 3 after administration. No clinical signs and
- Gross pathology:
- The following macroscopic pathologic finding was observed in one animal that died (500 mg/kg: 1 female): red erosion/ulcer, in the glandular stomach, diameter 3 mm. No macroscopic pathologic abnormalities were noted in the other animal that died (500 mg/kg: 1 female) and in the animals examined at the end of the observation period (500 mg/kg: 1 female; 300 mg/kg: 6 females).
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of this study the median lethal dose of 1-Aminotetralin after oral administration was found to be greater than 300 mg/kg and less than 500 mg/kg body weight in rats.
- Executive summary:
The study was performed to assess the acute toxicity following oral administration of 1-Aminotetralin in Wistar rats. Single doses of 500 and 300 mg/kg body weight of test material preparations in olive oil Ph.Eur./DAB were given to three administration groups of three fasted female animals, each, (500 mg/kg in 3 females, 300 mg/kg in 6 females) by gavage in a sequential manner. Two animals of the 500 mg/kg administration group were found dead within 4 hours after application. No mortality occurred in the 300 mg/kg administration groups. Clinical observation in one animal of the 500 mg/kg administration group revealed poor general state, dyspnoea, lateral position, clonic convulsions and salivation. Findings were observed from hour 1 through to hour 3 after administration. No clinical signs and findings were observed in another animal of the 500 mg/kg administration group that died because lethality occurred immediately after administration. In addition no clinical signs and findings were observed in the surviving animal of the 500 mg/kg administration group. Clinical observation in the first 300 mg/kg administration group revealed impaired or poor general state, dyspnoea, lateral position, staggering, ataxia, rolling or clonic convulsions and smeared fur. Findings were observed from hour 0 through to study day 2 after administration. Clinical observation in the second 300 mg/kg administration group revealed impaired general state, dyspnoea and piloerection. Findings were observed from hour 1 through to study day 1 after administration. The body weight of the surviving animal of the 500 mg/kg administration group increased during the first post exposure observation week but did not adequately increase during the second week. The mean body weights of the 300 mg/kg administration groups increased throughout the study period. During necropsy one animal that died in the 500 mg/kg administration group showed red erosion/ulcer in the glandular stomach. No macroscopic pathologic abnormalities were noted in the other animal that died (500 mg/kg: 1 female) and in the animals examined at the end of the observation period (500 mg/kg: 1 female; 300 mg/kg: 6 females). Under the conditions of this study the median lethal dose of 1-Aminotetralin after oral administration was found to be greater than 300 mg/kg and less than 500 mg/kg body weight in rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
